IPO listing: Mankind Pharma jumped high
Mankind Pharma surged 20% on market debut
Posted by NILESH WAGHELA
Mumbai: Mankind Pharma Ltd surged 20% on its stock market debut. Global brokerage firm Macquarie initiated coverage with an "outperform" rating ahead of its listing, citing sales outperformance and improved productivity as growth drivers.
Mankind Pharma got listed at 20% premium to the IPO price. The primary market saw an IPO hitting after a long gap, thus the interest was high.
Moreover, the healthcare sector was a laggard over last one year but started seeing traction over last two months as the monthly pharma data showed improvement.
Thus, Mankind Pharma received good response from its anchor clients given its domestic-focused business with strong brand recall in both chronic and consumer healthcare segment.
Given its healthy financial track record, domestic focus and extensive network, Mankind is likely to continue doing well.
- Hemang Jani, Head of Equity Strategy, Motilal Oswal Financial Services, said on Mankind Pharma listing.
Comments
Post a Comment